Brokerages Anticipate Dova Pharmaceuticals Inc (DOVA) Will Announce Quarterly Sales of $4.79 Million
Analysts forecast that Dova Pharmaceuticals Inc (NASDAQ:DOVA) will announce sales of $4.79 million for the current quarter, according to Zacks. Four analysts have made estimates for Dova Pharmaceuticals’ earnings, with estimates ranging from $4.00 million to $5.67 million. The company is expected to issue its next earnings report on Thursday, February 21st.
According to Zacks, analysts expect that Dova Pharmaceuticals will report full-year sales of $12.18 million for the current fiscal year, with estimates ranging from $11.00 million to $13.18 million. For the next year, analysts forecast that the business will post sales of $58.85 million, with estimates ranging from $41.00 million to $74.92 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Dova Pharmaceuticals.
Dova Pharmaceuticals (NASDAQ:DOVA) last announced its quarterly earnings data on Thursday, November 8th. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.12. The company had revenue of $2.93 million for the quarter, compared to analyst estimates of $2.66 million.
Several institutional investors and hedge funds have recently modified their holdings of DOVA. Metropolitan Life Insurance Co. NY bought a new position in shares of Dova Pharmaceuticals in the 2nd quarter worth $128,000. Stonepine Capital Management LLC bought a new position in shares of Dova Pharmaceuticals in the 3rd quarter worth $145,000. Tower Research Capital LLC TRC bought a new position in shares of Dova Pharmaceuticals in the 3rd quarter worth $158,000. Bank of America Corp DE lifted its holdings in shares of Dova Pharmaceuticals by 81.3% in the 2nd quarter. Bank of America Corp DE now owns 5,305 shares of the company’s stock worth $159,000 after purchasing an additional 2,379 shares in the last quarter. Finally, MetLife Investment Advisors LLC bought a new position in shares of Dova Pharmaceuticals in the 2nd quarter worth $181,000. Institutional investors own 37.14% of the company’s stock.
Shares of DOVA stock traded down $0.29 during trading hours on Monday, hitting $14.42. 4,590 shares of the company were exchanged, compared to its average volume of 191,923. The company has a market cap of $414.88 million, a price-to-earnings ratio of -10.29 and a beta of 0.71. Dova Pharmaceuticals has a fifty-two week low of $14.09 and a fifty-two week high of $37.00. The company has a quick ratio of 7.40, a current ratio of 7.50 and a debt-to-equity ratio of 0.17.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.
Further Reading: What does earnings per share mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.